Blog
RSS FeedPosted by Michael Wonder on 07 Jun 2017
New UK law to control generic drug prices – implications for pharma
7 June 2017 - New UK regulation seeks to clarify and extend the Government’s powers to regulate the cost of medicines ...
Posted by Michael Wonder on 07 Jun 2017
Alarming variations in treatment signal need for reforms
7 June 2017 - A new report showing dramatic differences in treatment rates around Australia signals a pressing need for ...
Posted by Michael Wonder on 07 Jun 2017
Actuaries push for insurers to pay cancer patients upfront
8 June 2017 - The Actuaries Institute and the Prostate Cancer Foundation of Australia are calling for private health insurers ...
Posted by Michael Wonder on 07 Jun 2017
Cancer Drugs Fund of minimal benefit
6 June 2017 - A new study has concluded that the medicines available in the previous version of the NHS Cancer ...
Posted by Michael Wonder on 06 Jun 2017
NICE backs Allergan’s Ozurdex, AbbVie’s Humira for uveitis
6 June 2017 - Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex ...
Posted by Michael Wonder on 06 Jun 2017
Research backs case for health insurance discount for young
6 June 2017 - Young people are more likely to take out health insurance if offered a discount, new research ...
Posted by Michael Wonder on 06 Jun 2017
Proposal to list a range of orthopaedic implants and associated products supplied by Johnson & Johnson
6 June 2017 - PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated ...
Posted by Michael Wonder on 06 Jun 2017
Transitional arrangements for General Schedule deletions and replacements - 1 June 2017 PBS Schedule
6 June 2017 - Transitional arrangements have been made for the delisting of two items from the PBS. ...
Posted by Michael Wonder on 05 Jun 2017
CADTH publishes final outcome for Gazyva for new indication
2 June 2017 - The Canadian pERC has recommended the funding of obinutuzumab (Gazyva) for use by adults with non-Hodgkin's ...
Posted by Michael Wonder on 05 Jun 2017
Deadline approaching
5 June 2017 - Final date close for submissions to controversial drug post-marketing review. ...
Posted by Michael Wonder on 05 Jun 2017
Top medicines panel benefits from second consumer representative
2 June 2017 - The appointment of a second consumers representative to the Pharmaceutical Benefits Advisory Committee recognises the value ...
Posted by Michael Wonder on 04 Jun 2017
Canberra girl with cystic fibrosis lobbies the Federal Government to give all access to the drug Orkambi
2 June 2017 - Twelve-year-old Canberra girl Bella Mitchell is more than aware how lucky she is to be on ...
Posted by Michael Wonder on 04 Jun 2017
Agenda for 7 June 2017 TC meeting
2 June 2017 - HAS has posted the agenda for the next scheduled TC meeting. ...
Posted by Michael Wonder on 03 Jun 2017
Recommendation made by the PBAC - April 2017
2 June 2017 - PBAC publishes single outcome from out of session meeting. ...
Posted by Michael Wonder on 02 Jun 2017
NICE backs Opdivo for classical Hodgkin lymphoma
2 June 2017 - Patients with classical Hodgkin lymphoma living in England and Wales could now become the first to ...